MAQS advised IRLAB Therapeutics on its rights issue

MAQS Advokatbyrå is advising IRLAB Therapeutics in connection with an 85 percent secured rights issue of shares of approximately SEK 136 million, as well as restructuring of loan financing.

IRLAB is a Swedish biopharmaceutical company developing new innovative treatments for the various symptoms that arise during the progression of Parkinson’s disease, where there is currently a lack of or only limited treatment options available. The Company has a broad portfolio of drug candidates, with several candidates ready for or nearing out-licensing/partnership. IRLAB is listed on Nasdaq Stockholm.

The MAQS team consists of Dag Fredlund, Fredrik Brusberg, and Rebecca Malm.